Abstract: The invention provides antibody-drug conjugates comprising an antibody conjugated to a 1-(chloromethyl)-2,3-dihydro-1H-benzo[e]indole (CBI) dimer drug moiety via a linker, and methods of using the antibody-drug conjugates.
Type:
Grant
Filed:
June 14, 2016
Date of Patent:
January 28, 2020
Assignee:
Genentech, Inc.
Inventors:
John A. Flygare, Thomas H. Pillow, Brian Safina, Vishal Verma, BinQing Wei, William Denny, Anna Giddens, Ho Lee, Guo-Liang Lu, Christian Miller, Gordon Rewcastle, Moana Tercel, Muriel Bonnet
Abstract: Methods and compositions are provided for preparing a biological specimen for microscopic analysis. These methods find many uses, for example in medicine and research, e.g., to diagnose or monitor disease or graft transplantation, to study healthy or diseased tissue, to screen candidate agents for toxicity and efficacy in disease modification. Also provided are reagents, devices, kits and systems thereof that find use in practicing the subject methods.
Type:
Grant
Filed:
March 13, 2013
Date of Patent:
January 28, 2020
Assignee:
The Board of Trustees of the Leland Stanford Junior University
Abstract: The present invention provides novel and advantageous compositions having a linker capable of covalently coupling one or more free thiols of an antibody. Specifically, provided herein are the molecular structures, synthetic pathways, coupling mechanisms, and applications thereof as used in an antibody-drug conjugate (ADC).
Type:
Grant
Filed:
August 15, 2016
Date of Patent:
January 21, 2020
Assignee:
RC BIOTECHNOLOGIES, INC.
Inventors:
Chang Jiang Huang, Jianmin Fang, Hui Ye, Lezhi Zhang
Abstract: This invention relates to peptidomimetic linkers and anti-body drug conjugates thereof, pharmaceutical compositions containing them, and to their use in therapy for the prevention treatment of cancer.
Type:
Grant
Filed:
December 16, 2014
Date of Patent:
January 14, 2020
Assignees:
Genentech Inc., Medimmune Limited
Inventors:
John Flygare, Janet Gunzner-Toste, Thomas Pillow, Brian Safina, Vishal Verma, Binqing Wei, Guiling Zhao, Leanna Staben, Philip Wilson Howard, Luke Masterson
Abstract: Benzazepine compounds, conjugates, and pharmaceutical compositions for use in the treatment of disease, such as cancer, are disclosed herein. The disclosed benzazepine compounds are useful, among other things, in the treating of cancer and modulating TLR8. Additionally, benzazepine compounds incorporated into a conjugate with an antibody construct are described herein.
Type:
Grant
Filed:
May 7, 2018
Date of Patent:
December 31, 2019
Assignee:
SILVERBACK THERAPEUTICS, INC.
Inventors:
Craig Alan Coburn, Peter Robert Baum, Sean Wesley Smith
Abstract: The present disclosure provides an anti-infective protector containing at least one anti-infective agent. The anti-infective protector provides for a range of benefits not appreciated in the prior art.
Abstract: In certain embodiments, the disclosure relates to methods of treating or preventing a PGAM1 mediated condition such as cancer or tumor growth comprising administering an effective amount of PGAM1 inhibitor, for example, an anthracene-9,10-dione derivative to a subject in need thereof. In certain embodiments, the disclosure relates to methods of treating or preventing cancer, such as lung cancer, head and neck cancer, and leukemia, comprising administering a therapeutically effective amount of a pharmaceutical composition comprising a compound disclosed herein or pharmaceutically acceptable salt to a subject in need thereof.
Abstract: This disclosure relates to compounds containing both an NO-releasing moiety and an H2S-releasing moiety and the use of such compounds in treating inflammatory diseases, including cancers.
Type:
Grant
Filed:
May 25, 2017
Date of Patent:
October 22, 2019
Assignee:
Research Foundation of The City University of New York
Abstract: The present disclosure provides various molecular constructs having a targeting element and an effector element. Methods for treating various diseases using such molecular constructs are also disclosed.
Abstract: Methods, compositions and uses are provided for bispecific antibodies comprising one or more unnatural amino acids. The bispecific antibodies may bind to two or more different receptors, co-receptors, antigens, or cell markers on one or more cells. The bispecific antibodies may be used to treat a disease or condition (e.g., cancer, autoimmune disease, pathogenic infection, inflammatory disease). The bispecific antibodies may be used to modulate (e.g., stimulate or suppress) an immune response.
Type:
Grant
Filed:
March 14, 2014
Date of Patent:
July 16, 2019
Assignee:
The Scripps Research Institute
Inventors:
Chanhyuk Kim, Jun Y. Axup, Hwayoung Yun, Peter G. Schultz, Jennifer Ma, Jiayin Shen, Pengyu Yang
Abstract: The present invention relates to therapeutic conjugates with improved ability to target various diseased cells containing a targeting moiety (such as an antibody or antibody fragment), a linker and a therapeutic moiety, and further relates to processes for making and using the conjugates.
Type:
Grant
Filed:
February 14, 2019
Date of Patent:
June 18, 2019
Assignee:
Immunomedics, Inc.
Inventors:
Serengulam V. Govindan, Sung-Ju Moon, David M. Goldenberg
Abstract: A polymeric scaffold useful for conjugating with a protein based recognition-molecule (PBRM) to form a PBRM-polymer-drug conjugate is described herein. The scaffold includes one or more terminal maleimido groups. Also disclosed is a PBRM-polymer-drug conjugate prepared from the scaffold. Compositions comprising the conjugates, methods of their preparation, and methods of treating various disorders with the conjugates or their compositions are also described.
Type:
Grant
Filed:
October 10, 2014
Date of Patent:
June 11, 2019
Assignee:
Asana BioSciences, LLC
Inventors:
Roger A. Smith, Nitin K. Damle, Aleksandr V. Yurkovetskiy, Mao Yin, Timothy B. Lowinger, Joshua D. Thomas, Cheri A. Stevenson, Venu R. Gurijala
Abstract: The present invention relates to therapeutic conjugates with improved ability to target various diseased cells containing a targeting moiety (such as an antibody or antibody fragment), a linker and a therapeutic moiety, and further relates to processes for making and using the conjugates.
Type:
Grant
Filed:
July 25, 2018
Date of Patent:
April 23, 2019
Assignee:
Immunomedics, Inc.
Inventors:
Serengulam V. Govindan, Sung-Ju Moon, David M. Goldenberg
Abstract: It is intended to provide an antitumor drug having an excellent therapeutic effect, which is excellent in terms of antitumor effect and safety. There is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an anti-TROP2 antibody via a linker having a structure represented by the following formula: -L1-L2-LP-NH—(CH2)n1-La-(CH2)n2-C(?O)— wherein the anti-TROP2 antibody is connected to the terminal of L1, and the antitumor compound is connected to the carbonyl group of the —(CH2)n2-C(?O)— moiety with the nitrogen atom of the amino group at position 1 as a connecting position.
Type:
Grant
Filed:
November 22, 2017
Date of Patent:
March 12, 2019
Assignees:
DAIICHI SANKYO COMPANY, LIMITED, SAPPORO MEDICAL UNIVERSITY
Inventors:
Toshinori Agatsuma, Shu Takahashi, Jun Hasegawa, Daisuke Okajima, Hirofumi Hamada, Miki Yamaguchi
Abstract: As an antitumor drug which is excellent in terms of antitumor effect and safety, there is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an antibody via a linker having a structure represented by the following formula: -L1-L2-LP-NH—(CH2)n1-La-Lb-Lc- wherein the antibody is connected to the terminal of L1, and the antitumor compound is connected to the terminal of Lc with the nitrogen atom of the amino group at position 1 as a connecting position.
Abstract: The invention provides antibody-drug conjugates comprising an antibody conjugated to an anthracycline drug moiety via a disulfide linker, anthracycline disulfide intermediates, and methods of using the antibody-drug conjugates.
Abstract: As an antitumor drug which is excellent in terms of antitumor effect and safety, there is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an antibody via a linker having a structure represented by the following formula: -L1-L2-LP-NH—(CH2)n1-La-Lb-Lc- wherein the antibody is connected to the terminal of L1, and the antitumor compound is connected to the terminal of Lc with the nitrogen atom of the amino group at position 1 as a connecting position.
Abstract: The present invention relates to a class of hydroxamic acid compounds of Formula (I), which act as alkylating agents and/or inhibitors of the HDAC pathway, having potential utility in the treatment of a neoplastic disease and immune diseases.
Abstract: The present invention relates to the combination of soluble ?-glucan and anti-cancer agents that affect the tumor microenvironment. Soluble ?-glucan promotes an immunostimulatory environment, which allows enhanced effectiveness of anti-cancer agents.
Type:
Grant
Filed:
December 21, 2016
Date of Patent:
October 30, 2018
Assignee:
BIOTHERA, INC.
Inventors:
Nandita Bose, Keith Gorden, Anissa S H. Chan, Steven Leonardo, Jeremy Graff, Xiaohong Qiu, Takashi Kangas, Kathryn A. Fraser, Adria Bykowski Jonas, Nadine Ottoson, Ross Fulton
Abstract: This disclosure relates to the combination of soluble ?-glucan and immune suppression-relieving agents that affect the tumor microenvironment. Soluble ?-glucan promotes an immunostimulatory environment, which allows enhanced effectiveness of anti-angiogenics, checkpoint inhibitors including non-tumor targeting antibodies.
Type:
Grant
Filed:
December 21, 2016
Date of Patent:
October 30, 2018
Assignee:
BIOTHERA, INC.
Inventors:
Nandita Bose, Keith Gorden, Anissa Sh. Chan, Steven Leonardo, Jeremy Graff, Xiaohong Qiu, Takashi Kangas, Kathryn A. Fraser, Adria Bykowski Jonas, Nadine Ottoson, Ross Fulton